"Informed AI News" is an publications aggregation platform, ensuring you only gain the most valuable information, to eliminate information asymmetry and break through the limits of information cocoons. Find out more >>
Semaglutide Shows Reduced Covid-19 Death Risk in Studies
- summary
- score
People on semaglutide, a key component of Ozempic and Wegovy, had a 33% lower risk of dying from Covid-19, according to studies in the Journal of the American College of Cardiology. Semaglutide, manufactured by Novo Nordisk, also demonstrated benefits for heart and kidney health, and reduced deaths from non-heart causes by 29%.
The drug appears to enhance overall health, with weight loss almost as a side effect. Benjamin Scirica, a study co-author, noted that weight was not a major factor in these benefits. The research involved over 17,600 overweight or obese individuals with heart issues, but not diabetes.
Novo Nordisk, now Europe's most valuable company, faces competition from Eli Lilly and others in the weight loss market. Yale's Harlan Krumholz suggests that semaglutide might work through multiple health-promoting mechanisms, but more research is needed.
Not all news is positive: Harvard found that weight loss drugs might increase the risk of a rare eye disease.
| Scores | Value | Explanation |
|---|---|---|
| Objectivity | 6 | Balanced reporting with comprehensive analysis. |
| Social Impact | 4 | Strong social discussion, influencing some public opinion. |
| Credibility | 5 | Solid evidence from authoritative sources. |
| Potential | 5 | Very high potential to trigger larger health-related events. |
| Practicality | 4 | Highly practical, applicable to real health problems. |
| Entertainment Value | 2 | Slightly monotonous, few entertaining elements. |